Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

B. Sigurgeirsson*, L. Kircik, O. Nemoto, I. Mikazans, S. Haemmerle, H. J. Thurston, C. Papavassilis, H. B. Richards

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

13 Citations (Scopus)
Original languageEnglish
Pages (from-to)1127-1129
Number of pages3
JournalJournal of the European Academy of Dermatology and Venereology
Volume28
Issue number8
DOIs
Publication statusPublished - Aug 2014

Cite this